JNJ : Analysis & Opinions

  • Showing 1-100 of 214 items
  • 1
  • 2
  • 3
  • >>
  1. Why All of the World's Top 10 Companies Are American

    November 11, 2015
    The top 10 companies in the world by market capitalization are all American, but history shows that such dominance in the ...
  2. Stocks to Eye with China's One-Child Policy Ended

    November 10, 2015
    Here are four stocks to consider in the wake of China ending its one-child policy.
  3. How Disney (DIS) Continues to Deliver

    November 4, 2015
    The Walt Disney Co. is only an animation studio in the same way that Johnson & Johnson is only a baby powder manufacturer.
  4. Johnson & Johnson: A Dividend King

    November 4, 2015
    Johnson & Johnson, a healthcare giant is a 'dividend king' and a stable stock, especially during volatile times.
  5. Johnson & Johnson Stock: A Dividend Analysis

    October 28, 2015
    Explore a detailed analysis of Johnson & Johnson's dividend policy, and learn about the dividend policies of its competitors, ...
  6. FDA's Warning Shakes Up Hep C Landscape

    October 23, 2015
    Yesterday, the FDA issued a warning highlighting the risk of potential serious liver injury with Viekira Pak, a drug used ...
  7. This Resilient Stock Should be on Your Watch List

    October 22, 2015
    If you’re looking to invest in a stock that offers resiliency, Johnson & Johnson should be on your radar. Here's why.
  8. Johnson & Johnson Earnings Disappoint

    October 13, 2015
    On October 13, 2015, healthcare giant Johnson & Johnson (JNJ) reported disappointing Q3 2015 results that fell short of analysts' ...
  9. The 5 Best Dividend Stocks in the Healthcare Sector

    October 7, 2015
    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash ...
  10. 3 Stocks that Are Top Bets for Retirement

    October 7, 2015
    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  11. Johnson & Johnson Cordis Sale Finalized

    October 5, 2015
    Johnson & Johnson (NYSE: JNJ) is now officially out of the heart products business, and Cardinal Health (NYSE: CAH) ...
  12. 4 Companies Affected by the Appreciating Dollar

    September 2, 2015
    Learn why the appreciating dollar negatively impacts certain companies such as Google, Facebook, Procter & Gamble and Johnson ...
  13. Top 3 Vanguard Managed ETFs

    August 17, 2015
    Find out which three Vanguard exchange-traded funds made into the list of best Vanguard products for new and established ...
  14. 3 Stocks to Protect Your Portfolio from Inflation

    August 13, 2015
    Discover three stocks to protect portfolios against inflation. The best companies to protect against inflation are those ...
  15. Pfizer Stock Is Like An Extended Release Drug

    August 12, 2015
    Pfizer is a leading research-driven pharmaceutical company, but how good is its financial health?
  16. Do Interest Rate Changes Affect Dividend Payers?

    July 21, 2015
    Interest rate changes have an effect on prices of dividend-rich stocks in interest rate sensitive sectors like utilities, ...
  17. 3 Reasons Johnson & Johnson Stock Could Rise

    July 1, 2015
    There are few companies these days that can truly be classified as "safe" investments, but I'd opine that healthcare conglomerate ...
  18. Could ASCO's New Ratings Boost J&J's Sales?

    June 23, 2015
    Johnson & Johnson (NYSE: JNJ) is battling for market share in the treatment of advanced prostate cancer, and a new ratings ...
  19. How High Could Johnson & Johnson's Dividend Go?

    June 17, 2015
    For retirees, income investors, and those investors with a risk-averse investing style, chances are that healthcare conglomerate ...
  20. Is This Johnson & Johnson's Next Blockbuster?

    June 10, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) may not be associated with high-growth biotech companies, but ...
  21. Why There's No Such Thing As A Stock 'Free Ride'

    June 4, 2015
    If you're not familiar with freeriding and you're trading stocks, you should be. Although it sometimes happens unintentionally, ...
  22. Buy and Hold: Comfortable, But Mind the Risks

    June 4, 2015
    Don't let the comfort of buying and holding blind you into hurting your portfolio.
  23. Could Johnson & Johnson Divest More Assets?

    June 2, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a veritable staple in a number of retirees' portfolios, providing ...
  24. Will Gilead's Hepatitis C Dominance Collapse?

    May 28, 2015
    The launch of two multibillion-dollar blockbuster HCV drugs in the past year and a half has firmly established Gilead Sciences (NASDAQ: ...
  25. Trade These Stocks on a Re-test of Breakout Level

    May 27, 2015
    You can't always catch the breakout. If you miss it, you can still get in. Here are 4 stocks to watch for your "second chance" ...
  26. Johnson & Johnson's 3 Most Important Numbers

    May 27, 2015
    There aren't many companies investors can buy that offer a true "set it and forget it" feel, but healthcare conglomerate ...
  27. Johnson & Johnson Seeks to Deliver 10 Blockbusters

    May 22, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) might be stuck in a bit of a trading range over the past year, ...
  28. Can This J&J Drug Reshape Schizophrenia Treatment?

    May 21, 2015
    Keeping schizophrenia patients on their medication is one of the biggest challenges facing mental health doctors. That means ...
  29. Which Dow Jones Stocks are Safe? Which are Risky?

    May 20, 2015
    In a situation where our sustained bull run could turn into a sell-off rather quickly, here are four somewhat safe Dow stocks ...
  30. Who are Pfizer's (PFE) main competitors?

    May 20, 2015
    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ...
  31. Houston, Johnson & Johnson May Have a Problem

    May 19, 2015
    When it comes to potential "safe haven" investments, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is often ...
  32. 7 Things Johnson & Johnson Wants You to Know

    May 12, 2015
    Last month, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) reported its first-quarter earnings results, essentially ...
  33. Countries Most Affected By A Strong U.S. Dollar

    May 6, 2015
    The U.S. dollar is still the most important currency in the world. It's used for trade, foreign reserves, and as a substitute ...
  34. 3 Top Pharma Stocks that Pay Regular Dividends

    May 1, 2015
    The low down on three big name, dividend-paying pharma stocks.
  35. How to Analyze Pharma Stock Fundamentals

    April 23, 2015
    What you need to know about analyzing the fundamentals of pharma stocks.
  36. Johnson & Johnson's New Billion-Dollar Blockbuster

    April 17, 2015
    Invokana, one of Johnson & Johnson's (NYSE: JNJ) newest drugs, was a bright spot in the company's otherwise lackluster ...
  37. Are J&J's Results a Harbinger of Things to Come?

    April 15, 2015
    Johnson & Johnson (NYSE: JNJ) has reported its first-quarter financial results, and those results, while solid, show ...
  38. Are Sales for This J&J Drug About to Stall?

    April 13, 2015
    Johnson & Johnson (NYSE: JNJ)is a global healthcare giant that racked up $32.3 billion in sales from pharmaceuticals ...
  39. Johnson & Johnson Earnings: 5 Key Things to Watch

    April 10, 2015
    Earnings season is readying to kick off in a big way, and within the health care sector most eyes are beginning to shift ...
  40. Gilead's Little Tweak Could Produce Big Revenue

    April 8, 2015
    Sometimes it's the little things companies do that can have the biggest impacts on their bottom line. Take Gilead Sciences ...
  41. 3 Long-Tail Growth Drivers for Johnson & Johnson

    April 6, 2015
    For the most part, Wall Street and investors love the Big Pharma sector. Large pharmaceutical companies often have diverse ...
  42. Four Key Pharmaceuticals ETFs To Consider

    March 25, 2015
    ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...
  43. Why These Could Be 2015's 10-Best Pharma Stocks

    March 17, 2015
    The pharmaceutical stocks covered here have significant potential going forward. Here's why.
  44. Traders Look To Dividend Funds (VIG)

    March 6, 2015
    When uncertainty creeps into the mind of an active trader it is not uncommon for this type of person to turn toward the safety ...
  45. How the S&P 500 and Russell 2000 Indexes Differ

    January 22, 2015
    The S&P 500 and Russell 2000 are used as benchmarks for broader segments of the U.S. stock market. Each index has its own ...
  46. Most Powerful And Influential Public Companies In 3 Metrics

    December 9, 2014
    There are many ways to rank the word's most powerful companies. Looking at market value, brand value or sales revenue are ...
  47. The Best Way Into Big Pharma? See This ETF (IHE)

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF (IHE), ...
  48. 3 Healthcare Stocks To Profit From An Aging America

    October 29, 2014
  49. 3 Healthcare Stocks To Hedge Against Rising Medical Costs

    October 29, 2014
  50. How do you compare the Dow Jones Industrial Average (DJIA) and ...

    October 2, 2014
    See how the Dow Jones Industrial Average and TSX Composite move according to factors in their respective countries and from ...
  51. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  52. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These ...

    August 27, 2014
    Let me start off today's issue with a warning... We're not trying to sound alarmist. It does absolutely zero good ...
  53. Is Now The Time For Momentum Stocks?

    July 11, 2014
    In active trading, strong trends can last longer than traders expect. This has led to a surge of purpose-built exchange traded ...
  54. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  55. How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  56. How Some Brands Come Back from Near Death

    April 17, 2014
    Some company brands manage to revive themselves, while others die and go to brand heaven.
  57. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  58. How To Smooth-Out Your Ride In The Stock Market

    March 3, 2014
    Volatility is back. For investors, this nasty problem of gyrating markets can be a real hindrance to your portfolio’s total ...
  59. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  60. 14 Companies That Have Raised Their Dividends For 50 Years Or ...

    September 10, 2013
    Imagine if you had bought these stocks 20 years ago.If you had, then right now you'd be earning dividend yields of... ...
  61. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  62. Medtronic Marking Time

    August 20, 2013
    Medtronic looks stuck in low-growth mode for now, but the shares look undervalued.
  63. Danaher Could Be Loading Up For A Bigger 2014

    August 14, 2013
    Danaher has the resources to make some major purchases, but prices and expectations may be a little high.
  64. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  65. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  66. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  67. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  68. Stryker Seems Back On Track

    July 19, 2013
    Stryker's revenue growth looks fine, but there are still pressures in the end markets.
  69. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  70. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  71. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  72. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  73. Intuitive Surgical's Miss Looks Systemic And Company-Specific

    July 9, 2013
    A surprising drop in U.S. system placements is going to put Intuitive Surgical in the penalty box.
  74. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  75. Rising 10-Year Yields Could Crush Popular Dividend ETFs

    June 21, 2013
    Seduced by backward-looking dividend increase streaks, investors have fallen in love with dividend ETFs such as the Vanguard ...
  76. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  77. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  78. Recent Financials May Not Be Entirely Fair To Hologic

    May 8, 2013
    Macro pressures are outweighing solid internal progress at Hologic.
  79. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  80. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  81. Kimberly-Clark Looks Way Too Expensive For What It Is

    April 22, 2013
    Kimberly-Clark's growth prospects make today's valuation hard to justify.
  82. Is Controversy About Robot-Assisted Surgery Showing In Intuitive ...

    April 19, 2013
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  83. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  84. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  85. P&G Rewards Longs With Better Sales And Stronger Margins

    January 30, 2013
    Procter & Gamble is delivering on its promises for better performances.
  86. What Do All-Time-Highs Indicate For These Stocks Going Forward?

    January 30, 2013
    Some well-known names are making all-time highs, and exhibiting very strong uptrends. The question is where to get in?
  87. Shabby Reporting And Questionable Prospects At Abbott Labs

    January 28, 2013
    Poor reporting and weak margins undermine the potential of Abbott.
  88. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  89. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  90. Medtronic's Growth Looks Good, But Can It Last?

    November 22, 2012
    Medtronic may not be a super grower anymore, but it's doing better than the Street seems to acknowledge
  91. Schiff Creates A Bidding War

    November 19, 2012
    Two weeks after Bayer offered to buy Schiff for $34 a share, Reckitt Benckiser is offering $42 a share. A bidding war has ...
  92. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  93. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  94. GE's Results Reflect An Industrial Slowdown, But Valuation Isn't ...

    October 23, 2012
    GE may have disappointed, but the company and its stock are both in good shape today.
  95. These Companies Have Raised Their Dividends for 50 Consecutive ...

    October 18, 2012
    Imagine if you had bought these stocks 20 years ago. If you had, then right now you'd be earning dividend yields of... 27%... ...
  96. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  97. The Long-Tail Value Of Supreme Brands

    September 25, 2012
    Brand value can make old products into incredible winners.
  98. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  99. Buffett Sold Almost $3 Billion of these 3 Well-Known Stocks

    August 16, 2012
    As one of the world's most successful and prolific investors, it's no wonder Warren Buffett is closely watched by the stock ...
  100. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  • Showing 1-100 of 214 items
  • 1
  • 2
  • 3
  • >>
Trading Center